The NCCs may make a focussed call for evidence on specific clinical questions or subquestions, after it has done initial searches. It will be able to make a call at any point during development of the guideline, and stakeholders will usually be given 4weeks to respond. The NCC will approach all registered stakeholders for this evidence. The NCC may not issue any calls for evidence for a guideline if the Guideline Development Group (GDG) feels it is not necessary. In addition, the NCCs will accept relevant confidential data for consideration by the GDG.
The draft scope is out for consultation with stakeholders. The scope defines what aspects of care the guideline will cover and to whom it will apply. If you wish to comment, you need to do so via one of the registered stakeholder organisations listed, by the deadline shown.
23 March 2012
NICE will fully update its clinical guideline on the pharmacological management of neuropathic pain in non-specialist settings in order to address ongoing uncertainties regarding the cost effectiveness of some of the recommended treatment options. The planned update is not related to the safety or clinical efficacy of the drugs. Until a further announcement is made, theoriginal guideline (CG96)continues to represent best practice for the NHS.
NICE guidelines [CG173]
Neuropathic pain - pharmacological management: GDG membership list